Author: McLean, Nev ; Liang, Jun ; Kleinheinz, Tracy ; Nannini, Michelle ; Friedman, Lori ; Li, Jun ; Liao, Jiangpeng ; Vinogradova, Maia ; Blake, Robert A ; Ray, Nick ; Zhang, Birong ; Mody, Vidhi ; Labadie, Sharada ; Kiefer, James R ; Ran, Yingqing ; Chang, Jae ; Goodacre, Simon ; Hartman, Steven J ; Wang, Tao ; Wai, John ; Zbieg, Jason R ; Sampath, Deepak ; Zhong, Yu ; Ortwine, Daniel F ; Yeap, Kuen ; Metcalfe, Ciara ; Rei Ingalla, Ellen ; Zheng, Xiaoping ; Lai, Tommy ; Roussel, Fabien ; Sambrone, Amy ; Wang, Xiaojing

Fulvestrant is an FDA-approved drug with a dual mechanism of action (MOA), acting as a full antagonist and degrader of the estrogen receptor protein. A significant limitation of fulvestrant is the dosing regimen required for efficacy. Due to its high lipophilicity and poor pharmacokinetic profile, fulvestrant needs to be administered through intramuscular injections which leads to injection site soreness. This route of administration also limits the dose and target occupancy in patients. We envisioned a best-in-class molecule that would function with the same dual MOA as fulvestrant, but with improved physicochemical properties and would be orally bioavailable. Herein we report our progress toward that goal, resulting in a new lead GNE-502 which addressed some of the liabilities of our previously reported lead molecule GNE-149.

11 Jun 2020·ACS Medicinal Chemistry LettersQ3 · MEDICINE

Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer

Q3 · MEDICINE

Article

Author: Vinogradova, Maia ; Yeap, Kuen ; Chang, Jae ; Friedman, Lori S. ; Mody, Vidhi ; Roussel, Fabien ; Nannini, Michelle ; Otwine, Daniel ; Zheng, Xiaoping ; Liang, Jun ; Labadie, Sharada ; Wai, John ; Blake, Robert ; Zhang, Birong ; Liao, Jiangpeng ; Wang, Tao ; Ran, Yingqing ; Kiefer, James R. ; Sampath, Deepak ; Li, Jun ; Goodacre, Simon ; Wang, Xiaojing ; Ingalla, Ellen Rei ; Young, Amy ; Ray, Nick ; Hartman, Steven ; Lai, Kwong Wah ; McLean, Neville ; Zhong, Yu ; Kleinheinz, Tracy ; Zbieg, Jason ; Sambrone, Amy ; Metcalfe, Ciara

Estrogen receptor alpha (ERα) is a well-validated drug target for ER-positive (ER+) breast cancer. Fulvestrant is FDA-approved to treat ER+ breast cancer and works through two mechanisms-as a full antagonist and selective estrogen receptor degrader (SERD)-but lacks oral bioavailability. Thus, we envisioned a "best-in-class" molecule with the same dual mechanisms as fulvestrant, but with significant oral exposure. Through lead optimization, we discovered a tool molecule 12 (GNE-149) with improved degradation and antiproliferative activity in both MCF7 and T47D cells. To illustrate the binding mode and key interactions of this scaffold with ERα, we obtained a cocrystal structure of 6 that showed ionic interaction of azetidine with Asp351 residue. Importantly, 12 showed favorable metabolic stability and good oral exposure. 12 exhibited antagonist effect in the uterus and demonstrated robust dose-dependent efficacy in xenograft models.

100 Deals associated with GNE-149

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer	Preclinical	US	Xidian University	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

GNE-149

Overview

Basic Info

Structure

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation